Source

"Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition met its goals in a late-stage trial... The company’s treatment uses Nobel Prize-winning technology Crispr to edit DNA and turn off the gene that controls production of a peptide that’s overactive in people with hereditary angioedema... Intellia’s treatment is administered once through an hourslong infusion, making the edits directly in the liver. Intellia said the one-time treatment reduced attacks by 87% compared with a placebo..." NASDAQ:NTLA

u/Betaversion · 2026-04-27T11:57:36.453Z